The FDA has approved the first at-home brain stimulation device for major depressive disorder. What does this mean for access, oversight, and patient selection? Dr. Victoria Hendrick reflects on how this newly approved headset could expand neuromodulation—while raising important clinical and reimbursement questions for hospital psychiatrists.

Is ketamine really more effective than an active placebo for inpatient depression? A new randomized trial puts ketamine head-to-head with midazolam, and the results may temper early enthusiasm.

Can continuation and maintenance ECT (c/mECT) reduce hospitalizations and healthcare costs? A large Danish study suggests it can, especially for patients with schizophrenia or treatment-resistant illness. Explore how c/mECT could reshape long-term care planning for your most complex cases.

There is no cure for major neurocognitive disorder (MND), but several medications mitigate the progression of cognitive and functional decline.